Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A01483 | 34729904 | Obes Rev | Gut microbiota and related metabolites in the pathogenesis of nonalcoholic steatohepatitis and its resolution after bariatric surgery. | 2021 | Details |
| A01489 | 34726820 | Intern Med J | Clinical relevance of Shear Wave Elastography compared with Transient Elastography and other markers of liver fibrosis - a cross-sectional study. | 2022 | Details |
| A01497 | 34723254 | JPGN Rep | Relationship of Vitamin D Deficiency and Fatty Liver in Children as Defined by Multiple Imaging and Histologic Endpoints. | 2021 | Details |
| A01500 | 34722175 | J Clin Transl Hepatol | Metabolic Disorders Combined with Noninvasive Tests to Screen Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A01501 | 34722019 | Cureus | Decoding the Pathophysiology of Non-alcoholic Fatty Liver Disease Progressing to Non-alcoholic Steatohepatitis: A Systematic Review. | 2021 | Details |
| A01502 | 34721326 | Front Microbiol | Disentangling the Progression of Non-alcoholic Fatty Liver Disease in the Human Gut Microbiota. | 2021 | Details |
| A01509 | 34717002 | Hepatology | Breviscapine alleviates NASH by inhibiting TGF-β-activated kinase 1-dependent signaling. | 2021 | Details |
| A01510 | 34716911 | Hormones (Athens) | Association of cardiovascular factors in diabetic patients with non-alcoholic fatty liver disease. | 2021 | Details |
| A01511 | 34715296 | Free Radic Biol Med | Role of vitamin E in the treatment of non-alcoholic steatohepatitis. | 2021 | Details |
| A01514 | 34712448 | Middle East J Dig Dis | Melatonin Levels in Patients with Nonalcoholic Fatty Liver Disease Compared with Healthy Individuals according to Fibrosis Level. | 2021 | Details |
| A01517 | 34711912 | Sci Rep | Loss of hepatic Flcn protects against fibrosis and inflammation by activating autophagy pathways. | 2021 | Details |
| A01521 | 34710382 | Am J Pathol | A Novel Mouse Model of Nonalcoholic Steatohepatitis Suggests that Liver Fibrosis Initiates around Lipid-Laden Macrophages. | 2021 | Details |
| A01524 | 34708231 | Sheng Li Xue Bao | [The role of SIRT6 in nonalcoholic steatohepatitis]. | 2021 | Details |
| A01528 | 34707622 | Front Immunol | Oral Pathobiont-Induced Changes in Gut Microbiota Aggravate the Pathology of Nonalcoholic Fatty Liver Disease in Mice. | 2021 | Details |
| A01529 | 34707573 | Front Endocrinol (Lausanne) | Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis. | 2021 | Details |
| A01538 | 34706243 | Cell Rep | Adenosine deaminase 2 produced by infiltrative monocytes promotes liver fibrosis in nonalcoholic fatty liver disease. | 2021 | Details |
| A01547 | 34697932 | J Korean Med Sci | Non-alcoholic Fatty Liver Disease and COVID-19 Susceptibility and Outcomes: a Korean Nationwide Cohort. | 2021 | Details |
| A01548 | 34697917 | Hepatol Commun | Perceptions of Exercise and Its Challenges in Patients With Nonalcoholic Fatty Liver Disease: A Survey-Based Study. | 2021 | Details |
| A01554 | 34695558 | J Nutr Biochem | Nobiletin mitigates hepatocytes death, liver inflammation, and fibrosis in a murine model of NASH through modulating hepatic oxidative stress and mitochondrial dysfunction. | 2021 | Details |
| A01557 | 34694029 | FASEB J | BTT-105 ameliorates hepatic fibrosis in non-alcoholic fatty liver animal model. | 2021 | Details |
| A01558 | 34694013 | Aliment Pharmacol Ther | Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis. | 2021 | Details |
| A01560 | 34693553 | J Gastroenterol Hepatol | Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study. | 2021 | Details |
| A01561 | 34693238 | JHEP Rep | Non-invasive biomarkers of Fontan-associated liver disease. | 2021 | Details |
| A01562 | 34693236 | JHEP Rep | Non-alcoholic fatty liver disease: A patient guideline. | 2021 | Details |
| A01563 | 34692739 | Front Med (Lausanne) | Hypoxia-Inducible Factors as Key Players in the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. | 2021 | Details |
| A01567 | 34690658 | J Taibah Univ Med Sci | Impact of standard treatment on the quality of life of non-alcoholic fatty liver disease patients. | 2021 | Details |
| A01568 | 34690105 | Rev Gastroenterol Mex (Engl Ed) | Fibrosis assessment in patients with nonalcoholic fatty liver disease: Adherence to proposed algorithms and barriers to complying with them. | 2021 | Details |
| A01570 | 34689689 | J Obstet Gynaecol | Non-alcoholic fatty liver disease in polycystic ovarian syndrome in Indian women. | 2021 | Details |
| A01571 | 34689362 | Hepatology | Switch-associated protein 70 protects against nonalcoholic fatty liver disease via suppression of TAK1. | 2022 | Details |
| A01574 | 34688661 | J Biol Chem | A retinoic acid receptor β2 agonist attenuates transcriptome and metabolome changes underlying nonalcohol-associated fatty liver disease. | 2021 | Details |
| A01581 | 34685636 | Cells | Oxysterol 7-α Hydroxylase (CYP7B1) Attenuates Metabolic-Associated Fatty Liver Disease in Mice at Thermoneutrality. | 2021 | Details |
| A01582 | 34685614 | Cells | Gut Microbiota-Related Cellular and Molecular Mechanisms in the Progression of Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A01587 | 34684533 | Nutrients | Supplementation with a Specific Combination of Metabolic Cofactors Ameliorates Non-Alcoholic Fatty Liver Disease, Hepatic Fibrosis, and Insulin Resistance in Mice. | 2021 | Details |
| A01588 | 34684510 | Nutrients | Indole-3-Propionic Acid, a Gut-Derived Tryptophan Metabolite, Associates with Hepatic Fibrosis. | 2021 | Details |
| A01589 | 34684463 | Nutrients | Relationship between Dietary Fatty Acid Intake with Nonalcoholic Fatty Liver Disease and Liver Fibrosis in People with HIV. | 2021 | Details |
| A01591 | 34684404 | Nutrients | Association between Fasting Ketonuria and Advanced Liver Fibrosis in Non-Alcoholic Fatty Liver Disease Patients without Prediabetes and Diabetes Mellitus. | 2021 | Details |
| A01599 | 34681787 | Int J Mol Sci | The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A01601 | 34681695 | Int J Mol Sci | Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity. | 2021 | Details |
| A01605 | 34681219 | Pharmaceuticals (Basel) | Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. | 2021 | Details |
| A01609 | 34680522 | Biomedicines | Lipid Disorders in NAFLD and Chronic Kidney Disease. | 2021 | Details |
| A01610 | 34680518 | Biomedicines | The Risk of Colorectal Adenoma in Nonalcoholic or Metabolic-Associated Fatty Liver Disease. | 2021 | Details |
| A01611 | 34680486 | Biomedicines | Nonalcoholic Fatty Liver Disease and the Kidney: A Review. | 2021 | Details |
| A01612 | 34680476 | Biomedicines | Genetics Is of the Essence to Face NAFLD. | 2021 | Details |
| A01615 | 34679664 | Antioxidants (Basel) | Dimeric Histidine as a Novel Free Radical Scavenger Alleviates Non-Alcoholic Liver Injury. | 2021 | Details |
| A01617 | 34679515 | Diagnostics (Basel) | The Diagnostic Accuracy of LOGIQ S8 and E9 Shear Wave Elastography for Staging Hepatic Fibrosis, in Comparison with Transient Elastography. | 2021 | Details |
| A01618 | 34679242 | Liver Int | Long-term prognosis of patients with alcohol-related liver disease or non-alcoholic fatty liver disease according to metabolic syndrome or alcohol use. | 2021 | Details |
| A01620 | 34678858 | Eur J Gastroenterol Hepatol | Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis. | 2022 | Details |
| A01627 | 34677008 | Hepatol Commun | Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A01628 | 34676692 | Hepatol Commun | Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. | 2021 | Details |
| A01631 | 34675931 | Front Immunol | Tim-1 Deficiency Aggravates High-Fat Diet-Induced Steatohepatitis in Mice. | 2021 | Details |
| A01637 | 34674510 | Endocrinol Metab (Seoul) | Changes in Insulin Resistance Index and the Risk of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease without Diabetes: Kangbuk Samsung Health Study. | 2021 | Details |
| A01638 | 34674097 | Inflammation | Deoxycholic Acid Promotes Pyroptosis in Free Fatty Acid-Induced Steatotic Hepatocytes by Inhibiting PINK1-Mediated Mitophagy. | 2021 | Details |
| A01639 | 34671996 | Aliment Pharmacol Ther | Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis. | 2021 | Details |
| A01644 | 34670043 | N Engl J Med | Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A01645 | 34670042 | N Engl J Med | A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. | 2021 | Details |
| A01646 | 34669440 | Sci Transl Med | Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. | 2021 | Details |
| A01648 | 34669068 | J Med Ultrason (2001) | MRI-derived proton density fat fraction. | 2021 | Details |
| A01650 | 34668658 | Hepatol Commun | Community Socioeconomic Deprivation Predicts Nonalcoholic Steatohepatitis. | 2021 | Details |
| A01651 | 34668597 | Hepatology | High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population. | 2021 | Details |
| A01652 | 34667947 | JHEP Rep | New targets for NAFLD. | 2021 | Details |
| A01656 | 34665792 | Clin Transl Gastroenterol | Sleep Duration, Sleep Quality, and the Development of Nonalcoholic Fatty Liver Disease: A Cohort Study. | 2021 | Details |
| A01661 | 34663793 | Nutr Diabetes | Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD. | 2021 | Details |
| A01665 | 34662732 | Environ Toxicol Pharmacol | Deciphering the toxicological role of Porphyromonas gingivalis derived endotoxins in liver diseases. | 2021 | Details |
| A01666 | 34662449 | Hepatology | Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. | 2022 | Details |
| A01670 | 34660454 | J Family Med Prim Care | Association of Obstructive Sleep Apnea with Nocturnal Hypoxemia in Metabolic-Associated Fatty Liver Disease Patients: A Cross-sectional Analysis of Record-based Data. | 2021 | Details |
| A01672 | 34659501 | Exp Ther Med | Non-alcoholic fatty liver disease and hematologic manifestations (Review). | 2021 | Details |
| A01673 | 34659439 | Evid Based Complement Alternat Med | Ginsenoside Re Improves Inflammation and Fibrosis in Hepatic Tissue by Upregulating PPARγ Expression and Inhibiting Oxidative Stress in db/db Mice. | 2021 | Details |
| A01680 | 34656650 | J Hepatol | Hepatocyte glutathione S-transferase mu 2 prevents non-alcoholic steatohepatitis by suppressing ASK1 signaling. | 2021 | Details |
| A01681 | 34656648 | Metabolism | CC chemokine ligand 3 deficiency ameliorates diet-induced steatohepatitis by regulating liver macrophage recruitment and M1/M2 status in mice. | 2021 | Details |
| A01683 | 34655465 | J Gastroenterol Hepatol | Altered bile acid glycine : taurine ratio in the progression of chronic liver disease. | 2021 | Details |
| A01684 | 34654976 | Curr Gastroenterol Rep | Dietary Approaches for Management of Non-Alcoholic Fatty Liver Disease: A Clinician's Guide. | 2021 | Details |
| A01700 | 34650994 | Front Med (Lausanne) | Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases. | 2021 | Details |
| A01706 | 34649219 | Biomed Pharmacother | Foresight regarding drug candidates acting on the succinate-GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment. | 2021 | Details |
| A01707 | 34648896 | J Hepatol | Dopamine receptor D2 antagonism normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis. | 2021 | Details |
| A01708 | 34648769 | Metabolism | Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. | 2021 | Details |
| A01711 | 34646672 | Cureus | Diagnostic Accuracy of FIB-4 and FIB-5 Scores as Compared to Fibroscan for Assessment of Liver Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A01713 | 34646360 | Therap Adv Gastroenterol | Diagnostic accuracy of two-dimensional shear wave elastography and transient elastography in nonalcoholic fatty liver disease. | 2021 | Details |
| A01716 | 34642957 | J Food Sci | Heukcha, naturally post-fermented green tea extract, ameliorates diet-induced hypercholesterolemia and NAFLD in hamster. | 2021 | Details |
| A01718 | 34641807 | BMC Geriatr | A low follicle-stimulating hormone level is a protective factor for non-alcoholic fatty liver disease in older men aged over 80. | 2021 | Details |
| A01719 | 34640643 | J Clin Med | Fibrosis Burden of Missed and Added Populations According to the New Definition of Metabolic Dysfunction-Associated Fatty Liver. | 2021 | Details |
| A01723 | 34638941 | Int J Mol Sci | MERTK+/hi M2c Macrophages Induced by Baicalin Alleviate Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A01724 | 34638880 | Int J Mol Sci | A Distinctive NAFLD Signature in Adipose Tissue from Women with Severe Obesity. | 2021 | Details |
| A01725 | 34638640 | Int J Mol Sci | Impact of Dietary Fat on the Progression of Liver Fibrosis: Lessons from Animal and Cell Studies. | 2021 | Details |
| A01726 | 34638217 | Zhonghua Gan Zang Bing Za Zhi | [Advances in the study of the role of adenosine 2A receptor in liver injury]. | 2021 | Details |
| A01733 | 34633706 | Hepatology | Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease. | 2021 | Details |
| A01737 | 34632357 | J Transl Autoimmun | Programmed cell death-1 rs11568821 and interleukin-28B rs12979860 polymorphisms in autoimmune hepatitis. | 2021 | Details |
| A01739 | 34631140 | Obes Sci Pract | "Bioelectrical impedance analysis in managing sarcopenic obesity in NAFLD". | 2021 | Details |
| A01740 | 34631129 | Obes Sci Pract | Addition of hyaluronic acid to the FIB-4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in type 2 diabetes: The Edinburgh Type 2 Diabetes Study. | 2021 | Details |
| A01742 | 34630901 | World J Diabetes | Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist? | 2021 | Details |
| A01747 | 34629804 | World J Gastroenterol | Screening for nonalcoholic fatty liver disease-when, who and how? | 2021 | Details |
| A01749 | 34629799 | World J Gastroenterol | Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. | 2021 | Details |
| A01755 | 34628896 | Ann Palliat Med | Accuracy of FibroTouch in assessing liver steatosis and fibrosis in patients with metabolic-associated fatty liver disease combined with type 2 diabetes mellitus. | 2021 | Details |
| A01758 | 34627976 | J Hepatol | Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease. | 2021 | Details |
| A01759 | 34627751 | Am J Pathol | Hepatic Steatosis in the Mouse Model of Wilson Disease Coincides with a Muted Inflammatory Response. | 2021 | Details |
| A01764 | 34626833 | Clin Gastroenterol Hepatol | Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis. | 2021 | Details |
| A01765 | 34626589 | J Lipid Res | Low production of 12α-hydroxylated bile acids prevents hepatic steatosis in Cyp2c70-/- mice by reducing fat absorption. | 2021 | Details |
| A01767 | 34624564 | Clin Gastroenterol Hepatol | Serum Fibrosis Tests Guide Prognosis in Metabolic Dysfunction-Associated Fatty Liver Disease Patients Referred From Primary Care. | 2021 | Details |
| A01770 | 34622555 | Diabetes Obes Metab | Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes. | 2021 | Details |
| A01778 | 34621052 | Nat Med | Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. | 2021 | Details |
| A01781 | 34619251 | J Hepatol | Asian perspective on NAFLD-associated HCC. | 2021 | Details |